01Approach to the Critical Patient/attcp54

Immediate priorities

›Life-threatening complication recognition

›Brucella endocarditis

›Responsible for >80% of brucellosis-related deaths

›Occurs in <2% of cases; aortic valve most commonly affected

›New cardiac murmur in febrile patient with risk factors requires urgent echocardiography

›Neurobrucellosis

›Meningoencephalitis, cranial nerve palsies, myelitis

›Occurs in 4-7% of cases

›Altered mental status, meningismus, focal neurological deficits

›Spondylodiscitis with epidural or paraspinal abscess

›Back pain with neurological deficits

›Cord compression risk requiring urgent MRI

›Severe sepsis and hemodynamic instability

›SBP <90 mmHg or MAP <65 mmHg

›Lactate >=2 mmol/l

›Initial stabilization priorities

›Airway and breathing

›Supplemental oxygen if SpO2 <92%

›Intubation if respiratory failure from pulmonary brucellosis or sepsis

›Circulation

›IV access and fluid resuscitation in shock

›Blood cultures prior to antibiotics when feasible

›Norepinephrine for refractory septic shock

›Notify microbiology lab of Brucella suspicion

›BSL-3 biosafety classification

›Extended incubation (>=7 days) required for blood cultures

02History/hx66

Exposure history

›Animal and occupational exposure

›Direct livestock contact

›Cattle, sheep, goats, pigs

›Exposure to birthing products or aborted fetuses

›Occupational risk groups

›Farmers, shepherds, veterinarians

›Slaughterhouse workers

›Laboratory personnel handling Brucella cultures

›Dietary exposure

›Unpasteurized milk, soft cheese, yogurt

›Accounts for 71% of cases in US outbreak series

›Geographic and travel history

›Middle East, Mediterranean basin

›Central and South America

›Sub-Saharan Africa, Indian subcontinent, Central Asia

›Recent immigration from endemic regions

Symptom characterization

›Classic presentation triad

›Undulant fever

›Characteristically rises in afternoon or evening

›Fever present in 64-93% of cases

›Drenching sweats often described as foul-smelling

›Arthralgias and myalgias

›Sacroiliac joint most commonly affected

›Hip, knee, lumbar spine involvement

›Constitutional symptoms

›Profound fatigue

03Physical Exam/exam53

Vital signs

›Hemodynamic and temperature assessment

›Temperature

›Fever in 64-93% of cases; undulant pattern

›Hypothermia as severe sepsis marker

›Blood pressure

›SBP <90 mmHg or MAP <65 mmHg indicates shock

›Heart rate

›Tachycardia proportional to fever and sepsis severity

›Respiratory rate

›Elevated in pulmonary complications or sepsis

Organ system examination

›Abdominal and lymph node examination

›Hepatomegaly

›Present in approximately 30% of patients

›Splenomegaly

›Present in 26-34% of patients

›Lymphadenopathy

›Present in approximately 10% of patients

›Musculoskeletal examination

›Sacroiliac joint tenderness

›FABER test for sacroiliac provocation

›Spinal tenderness

›Lumbar spine predominates, especially L4/L5

›Peripheral joint effusions

›Limited range of motion

›Genitourinary examination

›Testicular swelling and tenderness

04Differential Diagnosis/ddx49

Life-threatening mimics

›Infective endocarditis

›Non-Brucella causes

›ICD-10 I33.0

›Distinguish by blood culture organism identification

›New murmur with fever and embolic phenomena

›Tuberculous spondylitis

›ICD-10 A18.01

›Overlapping symptoms: fever, sweats, weight loss

›Both endemic in similar geographic regions

›Distinguish by PPD/IGRA, AFB cultures, vertebral imaging patterns

›Bacterial meningitis

›ICD-10 G00.9

›Fever, meningismus, altered mental status

›CSF analysis required for differentiation

›Splenic abscess with rupture

›ICD-10 D73.3

›Left upper quadrant pain with hemodynamic instability

Systemic febrile illness mimics

›Typhoid and enteric fever

›ICD-10 A01.0

›Similar undulant fever, travel history

›Blood cultures and Widal test differentiate

›Q fever (Coxiella burnetii)

›ICD-10 A78

›Similar zoonotic exposure, hepatitis, endocarditis risk

›Serology distinguishes

›Visceral leishmaniasis

05Laboratory Tests/lt53

Culture and definitive diagnosis

›Blood culture

›Gold standard for definitive diagnosis

›Sensitivity 15-70% using automated systems

›Extended incubation >=7 days required

›Notify lab of Brucella suspicion for BSL-3 precautions

›Bone marrow culture

›Highest sensitivity; considered true gold standard

›Invasive; reserved for culture-negative serology-confirmed cases

›PCR and nucleic acid amplification

›High sensitivity and specificity for rapid diagnosis

›May remain positive after clinical cure

›Limited utility for treatment monitoring

›Useful when serology is equivocal

Serology

›Standard agglutination testing

›Rose Bengal Test (RBT)

›Rapid screening with high sensitivity

›Ideal for point-of-care or field use

›Standard Tube Agglutination (SAT)

›Titer >=1:160 diagnostic in non-endemic areas

›Titer >=1:320 in endemic areas

›Class I consensus recommendation for initial serology

›Advanced serological tests

›ELISA (IgG and IgM)

›Sensitivity up to 98.7%; increasingly preferred

›Superior to bacterial culture and agglutination in endemic areas

›Brucellacapt

06Diagnostic Tests/dt73

Scoring Systems

›Disease phase classification

›Acute brucellosis

›Duration <8 weeks from symptom onset

›Subacute brucellosis

›Duration 8-52 weeks

›Chronic brucellosis

›Duration >12 months

›Often requires prolonged or retreatment regimens

›Risk stratification for poor prognosis

›Age >=45 years

›Associated with higher complication rates

›Back pain and joint tenderness

›Predictor of osteoarticular complications

›Delayed diagnosis

›Associated with focal complication development

›Endocarditis risk factors

›Pre-existing valvular heart disease

›Prosthetic valve

MRI

›MRI spine for spondylodiscitis

›Gold standard for brucellar spondylitis

›Findings include disc space narrowing and vertebral endplate erosion

›Paraspinal and epidural abscess detection

›Lumbar spine most commonly affected (especially L4/L5)

›Indications

›Back pain with neurological deficits

›Fever with spinal tenderness

07Disposition/dispo34

Admission indications

›Inpatient admission required

›Endocarditis or suspected endocarditis

›ICU-level care for hemodynamic instability

›Cardiac surgery consultation

›Neurobrucellosis

›Meningitis, encephalitis, focal neurological deficits

›Prolonged IV regimen required

›Severe sepsis or bacteremia with hemodynamic instability

›IV fluids and vasopressors

›Close monitoring for complications

›Spondylitis with epidural abscess or neurological compromise

›Urgent neurosurgical evaluation

›Significant cytopenias

›Severe anemia requiring transfusion

›Thrombocytopenia with bleeding risk

›Inability to tolerate oral medications

›Parenteral aminoglycoside requirement without outpatient infrastructure

Discharge criteria

›Outpatient management eligibility

›Uncomplicated acute brucellosis

›Hemodynamically stable

›No focal complications on initial workup

›Able to tolerate oral antibiotics reliably

›Reliable follow-up confirmed

›Infectious disease referral arranged

›Public health notification completed

08Treatment/t54

Antibiotic regimens - uncomplicated disease

›First-line regimen (gold standard for uncomplicated adult brucellosis)

›Doxycycline 100 mg PO BID for 6 weeks

›Plus streptomycin 1 g IM daily for 2-3 weeks

›Doxycycline plus streptomycin superior to doxycycline plus rifampin for preventing relapse

›Class I recommendation based on systematic review and meta-analysis

›Alternative if aminoglycoside unavailable

›Doxycycline 100 mg PO BID plus rifampin 600-900 mg PO daily, both for 6 weeks

›Higher relapse rate compared to streptomycin-containing regimen

›Gentamicin substitution for streptomycin

›Gentamicin 5 mg/kg/day IV or IM for 5-7 days

›Acceptable alternative when streptomycin unavailable

›Renal function monitoring required

Antibiotic regimens - complicated disease

›Spondylitis and other focal osteoarticular disease

›Triple therapy regimen

›Doxycycline plus rifampin plus levofloxacin or streptomycin

›Duration 12 weeks

›Reduces treatment failure and relapse versus dual therapy

›Relative risk 1.98-2.98 for dual versus triple therapy failure

›Neurobrucellosis regimen

›CNS-penetrating combination

›Doxycycline plus rifampin plus ceftriaxone 2 g IV daily

›Duration 3-6 months

›Ceftriaxone selected for superior CNS penetration

›Brucella endocarditis

›Prolonged combination therapy

›Doxycycline plus rifampin plus aminoglycoside

09Special Populations/sp46

Pregnancy

›Pregnancy-specific considerations

›Risk to pregnancy

›Brucellosis associated with miscarriage, preterm birth, intrauterine fetal death

›Vertical transmission possible

›Antibiotic regimen modifications

›Rifampin 900 mg PO daily with or without TMP-SMX for 6 weeks

›Doxycycline contraindicated: risk of fetal tooth discoloration and bone development effects

›Aminoglycosides relatively contraindicated: fetal ototoxicity risk

›TMP-SMX caution

›Avoid in first trimester (folate antagonism risk)

›Avoid near term (neonatal hyperbilirubinemia risk)

›Obstetrics consultation

›Fetal monitoring throughout treatment

›Delivery planning if near term

Geriatric

›Geriatric-specific considerations

›Atypical presentation

›Fever may be absent or blunted

›Confusion or delirium may be the primary presenting feature

›Complication risk

›Age >=45 years associated with higher complication rates and poor prognosis

›Pre-existing valvular disease increases endocarditis risk

›Pharmacologic considerations

›Renal function-adjusted aminoglycoside dosing

›Hepatic function assessment for rifampin

›Polypharmacy review for rifampin drug interactions

›Doxycycline generally well tolerated; esophageal irritation risk with decreased mobility

10Background/b69

Epidemiology

›Global burden

›Most common zoonotic infection worldwide

›Approximately 500,000 new cases annually

›Significant underreporting estimated

›Endemic regions

›Middle East, Mediterranean basin (highest burden)

›Central and South America

›Sub-Saharan Africa, Indian subcontinent, Central Asia

›Demographics

›Males affected 2-3 times more than females

›Peak age 30-69 years

›Predominantly occupational and dietary exposure patterns

›Mortality

›Overall mortality <2% with appropriate treatment

›Endocarditis accounts for >80% of brucellosis-related deaths

›Risk factors for poor prognosis: age >=45, back pain, joint tenderness, delayed diagnosis

›Relapse rate

›5-13% even with appropriate dual therapy

Pathophysiology

›Organism characteristics

›Brucella species

›Gram-negative intracellular coccobacilli

›Primary human pathogens: B. melitensis (goats/sheep), B. abortus (cattle), B. suis (pigs), B. canis (dogs)

›B. melitensis most virulent causing majority of human cases

›Biosafety classification

›BSL-3 pathogen

›Potential bioterrorism agent

›Infection mechanism

›Entry routes

›Ingestion of contaminated dairy products

›Direct contact with infected animal tissues (skin, mucosa, conjunctiva)

›Inhalation of aerosols (laboratory, abattoir settings)

›Intracellular survival

›Brucella resists macrophage killing by suppressing phagosomal acidification

›Replicates within macrophages and dendritic cells

›Evades immune detection via smooth LPS modification

›Dissemination

›Bacteremia from initial site of infection

›Seeding of reticuloendothelial system: liver, spleen, bone marrow, lymph nodes

›Focal complications arise from persistent intracellular infection

›Osteoarticular pathology

›Most common focal complication at 34-50% of cases

›Sacroiliac joint and lumbar spine predominate

›Mechanism: bacteremic seeding of richly vascularized bone

›Granuloma formation with eventual bone destruction

›Endocarditis pathology

›Aortic valve most commonly affected

›Large vegetations with high embolic potential

›Perivalvular abscess extension common

Therapeutic Considerations

›Rationale for combination therapy

›Brucella intracellular location requires drugs with intracellular penetration

›Doxycycline penetrates macrophages effectively

›Rifampin accumulates within phagosomes

›Monotherapy uniformly associated with unacceptable relapse

›Single-drug regimens never recommended

›Combination reduces relapse by targeting multiple phases of intracellular cycle

›Evidence base summary

›Cochrane systematic review (Yousefi-Nooraie et al., 2012)

›Doxycycline plus streptomycin superior to doxycycline plus rifampin for relapse prevention

›Network meta-analysis (Silva et al., 2024)

›Triple therapy further reduces failure and relapse versus dual regimens

›Meta-analysis (Maduranga et al., 2024)

›Relative risk 1.98-2.98 for dual versus triple therapy treatment failure

›Treatment monitoring

›Serologic titers at 3, 6, and 12 months post-treatment

›Rising titers suggest relapse

›PCR may remain positive after cure; not recommended for treatment monitoring alone

›Relapse management

›Occurs within 6 months of completing therapy in most cases

›Retreatment with different or intensified regimen required

11Patient Discharge Instructions/pdi28

copy discharge instructions

›Discharge instructions for Brucellosis

›Antibiotic course

›Take all antibiotic medications for the full prescribed duration (typically 6-12 weeks)

›Stopping antibiotics early is the leading cause of relapse

›Take doxycycline with a full glass of water and remain upright for 30 minutes to prevent esophageal irritation

›Food safety

›Avoid all unpasteurized dairy products permanently (milk, soft cheeses, yogurt)

›Avoid undercooked meat from livestock

›These are the most common sources of brucellosis infection

›Activity and recovery

›Fatigue and joint pain may persist for weeks to months after starting treatment

›Gradually increase activity as tolerated

›Follow-up appointment in 2 weeks to assess response to treatment

›Monitoring for relapse

›Blood tests will be needed at 3, 6, and 12 months after completing treatment

›Household contacts

›Other family members who shared the same dairy products or animal exposure should be seen by a doctor for screening

›Occupational safety

›If working with animals or in a laboratory, notify your occupational health department

›Use appropriate protective equipment when handling livestock or their products

›Return to emergency department immediately for

›Recurrence of fever or drenching sweats after initial improvement

›New or worsening back pain, joint pain, or difficulty walking

›Numbness, weakness, or loss of bladder or bowel control

›Chest pain, shortness of breath, or heart pounding

›Testicular swelling or pain

›Severe headache, neck stiffness, or confusion

12References/r23

Guidelines and key sources

›Primary references

›Franco MP, Mulder M, Gilman RH, Smits HL. Human Brucellosis. Lancet Infectious Diseases. 2007. PMID 18045560

›Comprehensive clinical review of brucellosis epidemiology, diagnosis, and treatment

›Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. New England Journal of Medicine. 2005

›Landmark NEJM review defining clinical management principles

›Yousefi-Nooraie R et al. Antibiotics for Treating Human Brucellosis. Cochrane Database of Systematic Reviews. 2012

›Evidence base for combination antibiotic superiority; doxycycline plus streptomycin versus alternatives

›Treatment evidence

›Silva SN et al. Efficacy and Safety of Therapeutic Strategies for Human Brucellosis. PLoS Neglected Tropical Diseases. 2024. PMID 38466771

›Network meta-analysis supporting triple therapy advantage

›Maduranga S et al. Systematic Review and Meta-Analysis of Comparative Clinical Studies on Antibiotic Treatment of Brucellosis. Scientific Reports. 2024. PMID 39152180

›RR 1.98-2.98 for dual versus triple therapy treatment failure

›Diagnostic and epidemiologic references

›Yagupsky P, Morata P, Colmenero JD. Laboratory Diagnosis of Human Brucellosis. Clinical Microbiology Reviews. 2019. PMID 31722888

›Comprehensive laboratory diagnostic approach including culture and serology

›Xu N et al. ELISA Is Superior to Bacterial Culture and Agglutination Test. BMC Infectious Diseases. 2020. PMID 31906870

›ELISA sensitivity up to 98.7% for brucellosis diagnosis

›Liu B et al. Epidemiology, Clinical Manifestations and Laboratory Findings in 1590 Brucellosis Cases. Frontiers in Microbiology. 2023. PMID 38088960

›Large case series defining prevalence of clinical features and lab abnormalities

›Shakir R. Brucellosis. Journal of the Neurological Sciences. 2021. PMID 33358192

›Neurobrucellosis epidemiology and management

›Jia B et al. Clinical Features of 590 Patients With Brucellosis in Xinjiang. PLoS Neglected Tropical Diseases. 2017. PMID 28459811

›Pediatric and complicated brucellosis treatment outcomes

Evidence & Review

Evidence & Review